Comparison of the vasodilatory effect of nadroparin, enoxaparin, dalteparin, and unfractioned heparin in human internal mammary artery

Journal of Cardiovascular Pharmacology

Volumn 45, Issue 6, 2005, Pages 550-554

  Tasatargil, Arda ^a   Ogutman, Caglar ^a   Golbasi, Ilhan ^a   Karasu, Edibe ^a   Dalaklioglu, Selvinaz ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Endothelium; Human internal mammary artery; Low molecular weight heparin; Nitric oxide; Unfractioned heparin; Vasorelaxation

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; ENOXAPARIN; HEPARIN; INDOMETACIN; LOW MOLECULAR WEIGHT HEPARIN; N(G) NITROARGININE METHYL ESTER; NADROPARIN; NITRIC OXIDE; PHENYLEPHRINE;

ANTICOAGULATION; ARTICLE; BLOOD SAMPLING; CONCENTRATION RESPONSE; CORONARY ARTERY BYPASS GRAFT; DRUG EFFECT; HUMAN; HUMAN TISSUE; INTERNAL MAMMARY ARTERY; LUNG EMBOLISM; PRIORITY JOURNAL; THROMBOSIS; VASCULAR SMOOTH MUSCLE; VASODILATATION;

DALTEPARIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENOXAPARIN; HEPARIN; HUMANS; MAMMARY ARTERIES; NADROPARIN; VASODILATION;

EID: 19544380400     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000159878.66325.fc     Document Type: Article

References (31)

1. Arjomantd H, Surabhi SK, Cohen M. Unfractioned versus fractioned heparin for percutaneous coronary intervention. Curr Cardiol Rep. 2002; 4:327-333.
2. Nurmohamed MT, ten Cate H, ten Cate JW. Low molecular weight heparin(oid)s. Clinical investigations and practical recommendations. Drugs. 1997;53:736-751.
3. Graf J, Janssens U. Low-molecular weight heparins in percutaneous coronary interventions: current concepts, problems, and perspectives. Curr Pharm Des. 2004;10:375-386.
4. Seltzer JI, Gerson JI. Decrease in arterial pressure following heparin injection prior to cardiopulmonary bypass. Acta Anaesthesiol Scand. 1979;23:575-578.
5. Hirsh J. Heparin. N Engl J Med. 1991;324:1565-1574.
6. von Segesser LK, Mueller X, Marty B, et al. Alternatives to unfractionated heparin for anticoagulation in cardiopulmonary bypass. Perfusion. 2001; 16:411-416.
7. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337: 688-698.
8. Hofmann T. Clinical application of enoxaparin. Expert Rev Cardiovasc Ther. 2004;2:321-337.
9. Wong GC, Giugliano RP, Antman EM. Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. JAMA. 2003;289:331-342.
10. Findik S, Erkan ML, Selcuk MB, et al. Low-molecular-weight heparin versus unfractioned heparin in the treatment of patients with acute pulmonary thromboembolism. Respiration (Herrlisheim). 2002;69:440-444.
11. Baumelou A, Singlas E, Petitclerc T, et al. Pharmacocinetics of a low molecular weight heparin (repivarine) in hemodialyzed patients. Nephron. 1994;68:202-206.
12. Ageno W, Turpie AGG. New advances in the management of acute coronary syndromes: 4. Low-molecular-weight heparins. Can Med Assoc J. 2002;166:919-923.
13. Tangphao O, Chalon S, Moreno HJ, et al. Heparin-induced vasodilation in human hand veins. Clin Pharmacol Ther. 1999;66:232-238.
14. Tasatargil A, Golbasi I, Sadan G, et al. Unfractioned heparin produces vasodilatory action on human internal mammary artery by endothelium-dependent mechanisms. J Cardiovasc Pharmacol. 2005;45:114-119.
15. Wang L, Li L, Shi Y, et al. Factor Xa inhibitory assay to detect plasma heparin concentrations during and after cardiopulmonary bypass. Sichuan Da Xue Xue Bao Yi Xue Ban. 2003;34:310-312.
16. Fareed J, Hoppensteadt D. Pharmacology of the low-molecular-weight heparins. Semin Thromb Hemost. 1996;22:13-18.
17. Mochizuki T, Olson PJ, Szlam F, et al. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg. 1998;87:781-785.
18. Despotis GJ, Levine V, Filos KS, et al. Hemofiltration during cardiopulmonary bypass: the effect on anti-Xa and anti-IIa heparin activity. Anesth Analg. 1997;84:479-483.
19. Cohen JA, Frederickson EL, Kaplan JA. Plasma heparin activity and antagonism during cardiopulmonary bypass with hypothermia. Anesth Analg. 1977;56:564-570.
20. Feletou M, Busse R, Edwards G, et al. Communacation between endothelial and smooth muscle cells. Med Sci (Paris). 2003;19:1242-1250.
21. Buzun L, Kleszczewski T, Kostrzewska A, et al. Influence of low molecular weight heparin preparations on human internal thoracic artery contraction. Eur J Cardiothorac Surg. 2004;26:951-955.
22. Ageno W, Turpie AG. New advances in the management of acute coronary syndromes: 4. Low-molecular-weight heparins. Can Med Assoc J. 2002; 166:919-924.
23. Sundaram M, Qi Y, Shriver Z, et al. Rational design of low-molecular weight heparins with improved in vivo activity. Proc Natl Acad Sci USA. 2003;100:651-656.
24. Shaughnessy SG, Young E, Deschamps P, et al. The effects of low molecular weight and standart heparin on calcium loss from fetal rat calvaria. Blood. 1995;86:1368-1373.
25. Chan P, Mill S, Mulloy B, et al. Heparin inhibition of human vascular smooth muscle cell hyperplasia. Int Angiol. 1992;11:261-267.
26. Quader MA, Stump LS, Sumpio BE. Low molecular weight heparins: current use and indications. J Am Coll Surg. 1998;187:641-658.
27. Dawes J. Interactions of heparins in the vascular environment. Haemostasis. 1993;23:212-219.
28. Young E, Wells P, Holloway S, et al. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractioned heparin. Thromb Haemost. 1994;71: 300-304.
29. Barzu T, Molho P, Tobelem G, et al. Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture. Nouv Rev Fr Hematol. 1984;26:243-247.
30. Kouretas PC, Hannan RL, Kapur NK, et al. Non-anticoagulant heparin increases endothelial nitric oxide synthase activity: role of inhibitory guanine nucleotide proteins. J Mol Cell Cardiol. 1998;30: 2669-2682.
31. Buhlmann AA. Pathophysiology of pulmonary embolism. Schweiz Med Wochenschr. 1984;114:1720-1724.